Aptose Biosciences Inc APS.TO
Jul 3, 2026, 3:46 PM EDT
- YTD
- +13.21%
- 1 year
- +112.39%
- Market cap
- 6.13M
- Shares out
- 59.52M
- Forward P/E
- -0.12
- YTD return
- +13.21%
- 1-year return
- +112.39%
- Volume
- 2.94K
- Avg volume
- 28.72K
- Open
- 2.40
- Previous close
- 2.40
- Day's range
- 2.40 – 2.40
- 52-week range
- 0.21 – 5.66
- Analysts
- Buy
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 0.4116
- 200-day average
- 0.97455
Analyst view
Consensus: buy
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.35.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 20, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- aptose.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on APS.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEJAR RAFAEL | Officer | Stock Award(Grant) | Jan 18, 2023 | 110,000 |
| LEDRU PHILIPPE | Officer | Stock Award(Grant) | Jan 18, 2023 | 100,500 |
| PAYNE CHARLES FLETCHER | Chief Financial Officer | Stock Award(Grant) | Jan 18, 2023 | 110,000 |
| RICE WILLIAM GLENN | Chief Executive Officer | Purchase | Nov 24, 2024 | 613,252 |
| SEIZINGER BERND R. | Director | Purchase | Sep 21, 2023 | 17,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 3.14% | 1,888,000 | 689.12K | Sep 29, 2024 |
| Drw Securities, Llc | 0.99% | 592,829 | 216.38K | Sep 29, 2024 |
| Sigma Planning Corp | 0.67% | 401,750 | 146.64K | Sep 29, 2024 |
| UBS Group AG | 0.22% | 133,476 | 48.72K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 0.13% | 77,340 | 28.23K | Sep 29, 2024 |
| Morgan Stanley | 0.05% | 31,353 | 11.44K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| DFA Investment Dimensions-Canadian Small Company Series | 0.00% | 767 | 279 | Jul 30, 2024 |